These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35423918)

  • 1. Evaluation of DNA segments in 2'-modified RNA sequences in designing efficient splice switching antisense oligonucleotides.
    Le BT; Agarwal S; Veedu RN
    RSC Adv; 2021 Apr; 11(23):14029-14035. PubMed ID: 35423918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
    Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
    Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
    Shadid M; Badawi M; Abulrob A
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing.
    Le BT; Paul S; Jastrzebska K; Langer H; Caruthers MH; Veedu RN
    Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2207956119. PubMed ID: 36037350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-
    Zhang L; Liang XH; De Hoyos CL; Migawa M; Nichols JG; Freestone G; Tian J; Seth PP; Crooke ST
    Nucleic Acid Ther; 2022 Oct; 32(5):401-411. PubMed ID: 35861704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model.
    Echevarría L; Aupy P; Relizani K; Bestetti T; Griffith G; Blandel F; Komisarski M; Haeberli A; Svinartchouk F; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Jun; 29(3):148-160. PubMed ID: 31009315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorothioate modification improves exon-skipping of antisense oligonucleotides based on sulfonyl phosphoramidates in
    Su Y; Raguraman P; Veedu RN; Filichev VV
    Org Biomol Chem; 2022 May; 20(18):3790-3797. PubMed ID: 35438707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
    Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
    Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro.
    Le BT; Adams AM; Fletcher S; Wilton SD; Veedu RN
    Mol Ther Nucleic Acids; 2017 Dec; 9():155-161. PubMed ID: 29246294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
    Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
    Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
    Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.
    Akpulat U; Wang H; Becker K; Contreras A; Partridge TA; Novak JS; Cirak S
    Mol Ther Nucleic Acids; 2018 Dec; 13():534-542. PubMed ID: 30396145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
    Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
    PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide.
    Chen S; Le BT; Rahimizadeh K; Shaikh K; Mohal N; Veedu RN
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27879669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.